2017 970 AD--

---1 -
PH
ES I
RECOMMENDATION

AS

LI
PP
E
C TI O U S D I S

INE
S O CI E T Y
Vaccina ion
for
ADULT IMMUNIZATION

FE
Foundation

FO
IN
D

R
Philippine MI
AN CR
O BI O L O GY

VACCINE TYPE/ROUTE TARGET INDIVIDUALS SCHEDULE PRECAUTIONS/CONTRAINDICATIONS

HUMAN PAPILLOMA Recommended for: • – for females

Bivalentonly • to severe
Moderate
acute illness
VIRUS (HPV) • 9-55 years
Females:
old – 9 to 13From
years old, 2 doses • allergic Severe
reaction to a vaccine
• vaccine
Recombinant • 10-26 years
Males:
old (0, 6 or 12 months) component or following a prior dose
• Intramuscular – be givenMay
as catch up vaccination to 13-21 years old who have – 13 years
Above
old, 3 doses (0, a woman
• is found
If pregnant after initiation of
not been previously vaccinated or who have not completed the 1, 6 months) the vaccine series, remaining doses should be
1. (Types
Bivalent
16, 3-dose series delayed until after the pregnancy
18) • – Quadrivalent
for males and
– only
Females females
2. Quadrivalent
(Types 6, doses
– 0, 2,3 6 months
11, 16, 18) 14 Females
to 45 years old
– andFemales
males 14 to Males
26 years old
doses,
– 9-13
2 years old. 0, 6 or
12 months

HERPES ZOSTER Recommended for: •as a singleGive

0.65 ml SC in the • Severe allergic reaction to a vaccine
VACCINE • ≥ 50 years
Adult
old and above with or without a prior episode of deltoid area component (gelatin or neomycin) or following a
Herpes Zoster those
• with history
For of herpes prior dose
•attenuatedLive,
VZV • with history
Persons of zoster (after 6 months to 1 year) zoster, vaccine may be given after • to severe
Moderate
acute illness
• Subcutaneous • with chronic
Persons medical conditions unless episode these at least 1 year of acute episode • Pregnancy
conditions are contraindications to vaccinate • Immunosuppressed
– renal
Chronic
failure • receipt Recent
of blood product
– mellitus
Diabetes • Thrombocytopenia/ITP
– Rheumatoid
arthritis • active
Untreated
tuberculosis
– pulmonary
Chronicdisease • with CD4 PLHIV
< 200 cells

MENINGOCOCCAL Recommended for: • immunocompetent,

For • For those with severe allergic reaction to the
• Polysaccharide
vaccine • travellingThose
to areas with meningococcal outbreaks dose 0.5single
ml. No vaccine component
(MPSV) • workersHealth
with contacts of meningococcal patients revaccination.
– Intramuscular
or • with immunocompromised
Those conditions and complement immunocompromised,
• If single
Subcutaneous dose 0.5 ml. Revaccination after 5
• Conjugate • or anantomic
Functionalasplenia years if there is risk of exposure.
vaccine(MCV4)
– Intramuscular

TYPHOID Recommended for: • Intramuscular

for primary and • Previous
anaphylactic reaction to vaccines or
• Intramuscular •handlers such
Food as dietary personnel cooks, waiters, servers, booster single 0.5 ml M dose on its components
capsular
• VI dieticians, nutritionists the deltiod
polysaccharide • labMicrobiology
technicians
• with intimate
Persons exposure to a documented S. typhi carrier or
patient

RABIES Recommended for: Pre-exposure

• series of 3 injections • Moderate
or severe acute illness
• Intramuscular/ on days 0, 7 & 21 or 28 • of corticosteroids,
Intake chemotherapeutic
Intradermal • care
Health
workers in hospitals that treat dog bites and rabies cases
• researchRabies
diagnostics/lab workers –on the deltoid
IM agents, antimalarials
• – HumanHDCV
diploid - 0.5 ml
PVRV
cell vaccine (Available • and
Veterinarian
vet students
•workers Field HDCV
PCECV,
- 1.0 ml
upon special request) – the deltoid
ID-on
•– PVRV
vero cell • childrenSchool
in areas with high incidence of rabies
PCECVPVRV,
- 0.1 ml
vaccine rabies • given only
Booster
to continuously
• – PCECV
chick exposed individuals
embryo vaccine - dose single
IM or ID every 2
years
post-exposure
• For prophylaxis -
refer to Standard guidelines

Anyone who desires to be protected can receive any of the vaccine unless contraindicated.
 O BI O L O GY
MI
CR AN Philippine
Foundation

D
FO

IN
for

FE
S O CI E T Y

C TI O U S D I S
INE
PP Vaccina ion

EA
LI

S
I ES
PH
---1 -
970 AD--